FindTrial
Sign In

Clinical comprehensive evaluation of linezolid injection based on real-world patient data: a multicenter, retrospective, cohort study

Clinical comprehensive evaluation of linezolid injection based on real-world patient data

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400087525
Enrollment
Unknown
Registered
2024-07-29
Start date
2024-08-01
Completion date
Unknown
Last updated
2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial Infectious Diseases

Interventions

Original-patented linezolid injection group:No intervention
domestic linezolid injection group:No intervention

Sponsors

Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients who were hospitalized and treated with linezolid injection for anti-infective treatment from January 1,2022 to December 31,2023. 2.Age greater than or equal to 18 years old.

Exclusion criteria

Exclusion criteria: 1.No infection occurred during admission ; 2.Using linezolid injection less than 48h.

Design outcomes

Secondary

MeasureTime frame
Serum drug concentration of linezolid;—

Primary

MeasureTime frame
Clinical cure rate;—

Countries

China

Contacts

Public ContactJinchun Liu

Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University

liujinchun@njglyy.com+86 180 0515 6530

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026